PARIS, France, January 25, 2023 at 6:30 p.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA)
(the “Company”), a late-stage biopharmaceutical company developing new therapies for neurodegenerative diseases without satisfactory therapeutic solution, announces that it has received an investment request (
Investor Call
) and proceeded with the issue of 100 bonds convertible into shares (the “OCA”) with a nominal value of €10,000 each under the contract for the issue of bonds convertible or exchangeable into new shares and/or existing assets (the “OCEANE-BSAs”) entered into with the company Global Tech Opportunities 13 (the “Investor”).
As for the funds received during the drawing of the previous tranches, the funds paid within the framework of this financing will be mainly used to finance the continuation of the PREMIER trial, a pivotal Phase III clinical study of PXT3003, the most advanced product of the Company in Charcot-Marie-Tooth disease type 1A, and the open-label Phase III extension study.
This financing is part of the agreement of June 4, 2021 relating to the issue of bonds convertible or exchangeable into new and/or existing shares accompanied by share subscription warrants (the “OCEANE-BSA”) , as amended in December 2021, in January 2022, in June 2022 and then on September 30, 2022.
As mentioned, Pharnext will be able to use the financing granted by Neovacs in order to supplement its monthly cash requirements.
The OCA monitoring tables, the number of newly issued shares for conversions, the total number of shares to be issued by the Company for the benefit of the Investor for conversions as well as the total number of shares in circulation are kept on the Company’s website (https://equityline.vox-aequitas.com/pharnext).
About Pharnext
Pharnext is a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases that currently have no satisfactory therapeutic solution. Pharnext has two products in clinical development. PXT3003 has completed an international Phase III trial with first positive results in Charcot-Marie-Tooth disease type 1A (CMT1A) and has orphan drug status in Europe and the United States. A pivotal international Phase III clinical study of PXT3003 in CMT1A, the PREMIER trial, is currently underway. PXT864 has obtained encouraging Phase II results in Alzheimer’s disease and its development will be pursued in partnerships. Pharnext’s two most advanced drug candidates were discovered with the Pleotherapy™ R&D approach. Pharnext draws investors’ attention to the risk factors, particularly the financial ones detailed in its financial reports. More information on www.pharnext.com.
Pharnext is listed on the Euronext Growth market in Paris (ISIN code: FR001400BV89).
contacts
|
Press Relations (International) Consilium Strategic Communications Mary Jane Elliott Sukaina Virji Alexandra Harrison [email protected] |
Financial Press Relations NEWS finance & communication Deborah Schwarz [email protected] +33 (0)1 53 67 36 35 |
Investor Relations NEWS finance & communication Jerome Fabreguettes Leib [email protected] +33 (0)1 53 67 36 78 |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
mZptlZqbk2idx26cYcmZa5Rrl29nk5aUmpXJxGeaacmcZ56VmJqVnJmeZnBpl2Zu
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Issuer operations (acquisitions, disposals, etc.)
Full and original press release in PDF format:
https://www.actusnews.com/news/78218-2023.01.25_ic_gto13_en.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com